Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Anthony Galeo

Interventional Cardiology Tucson, AZ Medical Doctor

NPI 1083647630 CMS profile 276169

6320 N La Cholla Blvd Ste 300, Ste 300, Tucson, AZ 85741

Open in the dashboard

General payments

$3,146

177 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Anthony Galeo of Tucson, AZ is reported in the CMS Open Payments database as having received $3,146 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,200 68
2023 General $711 40
2021 General $189 11
2020 General $484 29
2019 General $562 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Galeo
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Anthony Galeo were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Anthony Galeo Interventional Cardiology median Middle half National median
2019 $562 $1,097 $329–$3,048 $163
2020 $484 $473 $161–$1,480 $114
2021 $189 $677 $233–$1,827 $132
2022 $0 $978 $333–$2,724 $149
2023 $711 $1,136 $382–$2,986 $160
2024 $1,200 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $717 45 payments
  2. Abbott Laboratories $616 29 payments
  3. Novartis Pharmaceuticals Corporation $372 29 payments
  4. Janssen Pharmaceuticals, Inc $248 14 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $208 11 payments
  6. Boston Scientific Corporation $164 7 payments
  7. Kestra Medical Technology Services, Inc. $108 6 payments
  8. Baxter Healthcare $105 2 payments
  9. Amgen Inc. $97 6 payments
  10. Pfizer Inc. $91 5 payments
  11. Other $420 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,132 176 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2024
  1. LifeVest $717 45 payments
  2. XARELTO $248 14 payments
  3. LEQVIO $242 19 payments
  4. ASSURITY $165 10 payments
  5. Assurity Pacemaker $156 6 payments
  6. JARDIANCE $148 8 payments
  7. Assure WCD $108 6 payments
  8. Hillrom - Carnation Ambulatory Monitor $105 2 payments
  9. PressureWire FFR $104 1 payment
  10. Repatha $97 6 payments
  11. Other $1,226 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,770

Median for Interventional Cardiology: 2,236

Drug cost

$467,067

Median for Interventional Cardiology: $380,412

Branded share of claims

22.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 159 $204,274
Xarelto Rivaroxaban Brand 118 $144,941
Repatha Sureclick Evolocumab Brand 24 $27,344
Entresto Sacubitril/Valsartan Brand 25 $24,393
Brilinta Ticagrelor Brand 21 $23,817
Jardiance Empagliflozin Brand 19 $15,572
Metoprolol Succinate Generic 282 $4,163
Atorvastatin Calcium Generic 261 $2,222
Clopidogrel Clopidogrel Bisulfate Brand 140 $2,160
Losartan Potassium Generic 235 $1,990

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$82,850

Medicare's payments for the services billed

Medicare patients

575

Average age 78

Services billed

1,178

271 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 39%
Atrial fibrillation 36%
Chronic kidney disease 34%
Heart failure 28%
Diabetes 26%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $168
$168 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $103
$103 118 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $60
$60 25 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $47
$47 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
$46 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record